New 2- arylazoimidazoles derivatives as inhibitors of Trypanosoma cruzi growth: synthesis and biological evaluation

BLANCO, M.; LORENZO, M. G.; CARRILLO, J.; LÓPEZ, J.; GARCÍA VIOR, C.; SALERNO, A.

Athenas

Conferencia; 5th International BBBB Conference; 2013

September 26-28, 2013. Chagas disease is an insidious, potentially fatal parasitic disease that is widespread in Latin America affecting 10-14 millon or more. The current standard therapy nifurtimox or benznidazole is, at best, only minimally effective in chronic Chagas disease and it is associated with significant side effects. The development of new compounds is a clear need for a safe and effective drug for the treatment of chronic Chagas disease. Imidazoles, in general, are very promising trypanocidal drugs, but most of them are soluble only in organic solvents which, in most cases, are not allowed in pharmaceutical formulations. Since imidazoles are highly hydrophobic, delivery strategies have been developed to increase their solubility and improved their bioavailability.